Literature DB >> 24728890

Delayed onset of rotatory self-motion perception, dysdiadochokinesia and disturbed eye pursuit caused by low-dose pregabalin.

Patrice Hounnou1, Keyvan Nicoucar.   

Abstract

A 30-year-old woman with chronic foot pain after an orthopaedic surgery and chronic neck pain presented to the emergency department (ED) with a history of self-rotatory vertigo with unsteadiness. She had started low-dose pregabalin, 25 mg two times a day 9 months before experiencing symptoms with the dose gradually increased to 150 mg two times a day over this period. Clinical examination revealed difficulty performing eye pursuit with left eye and dysdiadochokinesia of the left arm. Owing to a suspicion of multiple sclerosis she underwent cerebral MRI, which was normal. Pregabalin was tapered over 2 months with a complete disappearance of the symptoms. We concluded that symptoms were due to pregabalin treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24728890      PMCID: PMC3987234          DOI: 10.1136/bcr-2013-201282

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

1.  Pregabalin abuse, dependence, and withdrawal: a case report.

Authors:  Martin Grosshans; Jochen Mutschler; Derik Hermann; Oliver Klein; Harald Dressing; Falk Kiefer; Karl Mann
Journal:  Am J Psychiatry       Date:  2010-07       Impact factor: 18.112

Review 2.  Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders.

Authors:  Daniel M Tassone; Eric Boyce; Jennifer Guyer; Donald Nuzum
Journal:  Clin Ther       Date:  2007-01       Impact factor: 3.393

3.  Pregabalin in the treatment of post-traumatic peripheral neuropathic pain: a randomized double-blind trial.

Authors:  R van Seventer; F W Bach; C C Toth; M Serpell; J Temple; T K Murphy; M Nimour
Journal:  Eur J Neurol       Date:  2010-03-04       Impact factor: 6.089

Review 4.  The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Gaetano Zaccara; Pierfranco Gangemi; Piero Perucca; Luigi Specchio
Journal:  Epilepsia       Date:  2011-02-14       Impact factor: 5.864

5.  Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain.

Authors:  Sabine Hellwig; Florian Amtage
Journal:  Epilepsy Behav       Date:  2008-05-19       Impact factor: 2.937

6.  Pregabalin-induced generalized myoclonic status epilepticus in patients with chronic pain.

Authors:  S Knake; K M Klein; K Hattemer; A Wellek; W H Oertel; H M Hamer; F Rosenow
Journal:  Epilepsy Behav       Date:  2007-09-27       Impact factor: 2.937

7.  Disturbance of consciousness and involuntary movements caused by pregabalin.

Authors:  Taro Shimizu; Tsuneyasu Yoshida; Koichi Kitamura; Osamu Hamada
Journal:  BMJ Case Rep       Date:  2012-11-28
  7 in total
  1 in total

1.  Low doses of amitriptyline, pregabalin, and gabapentin are preferred for management of neuropathic pain in India: is there a need for revisiting dosing recommendations?

Authors:  Sanjay Vasant Kamble; Salman Abdulrehman Motlekar; Lyndon Lincoln D'souza; Vinay Nanda Kudrigikar; Sameer Eknath Rao
Journal:  Korean J Pain       Date:  2017-06-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.